High Blood Pressure Medication Voluntarily Recalled: FDA

The U.S. Food and Drug Administration (FDA) has announced a voluntary recall of several high blood pressure medications due to potential contamination issues.

According to the FDA, some lots of valsartan-containing medications may contain N-nitrosodiethylamine (NDEA), a known animal carcinogen. The recall affects several medications manufactured by various companies in the U.S., including Sandoz, Teva Pharmaceuticals, and Mylan.

The FDA has not yet received any reports of adverse events related to the contaminated medication, but is taking proactive steps to ensure public safety. Consumers are advised to check their medication labels for the lot numbers listed on the FDA's website to determine if they have affected product.

It's essential to note that this recall only affects valsartan-containing medications and not other blood pressure medications.

Affected Products and Lot Numbers

• Sandoz Valsartan HCT, lot number DTZ5010A
• Teva Pharmaceuticals' Valturna, lot numbers TEV-14331 and TEV-14332
• Mylan's Amlodipine and Valsartan tablets, lot number Y0114E

As a precautionary measure, consumers are advised to consult with their healthcare provider or pharmacist before taking any medication. If you have questions about the recall or affected products, please visit our product information page for more details.